Are Glycemic Measures in the Nondiabetic Range Linked to NAFLD?
Increased blood glucose levels, even within the nondiabetic range, are associated with increased risk for nonalcoholic fatty liver disease.
Metabolic Liver Disease
METABOLIC LIVER DISEASE
Latest Articles
Noninvasive Scoring Systems May Identify Those at Risk for Severe Liver Disease
Noninvasive scoring systems have modest predictive ability to identify the future development of severe liver disease in patients in the general population.
Nonalcoholic Steatohepatitis Will Pose Clinical, Economic Burden
Nonalcoholic steatohepatitis (NASH) is expected to pose a significant clinical and economic burden during the next 20 years for U.S. patients with type 2 diabetes mellitus.
Patients With Nonalcoholic Fatty Liver Disease May Benefit From Daily Aspirin Use
In this prospective study of patients with biopsy-proven NAFLD, daily aspirin use was associated with less severe histologic features of NAFLD and NASH, and with lower risk for progression to advanced fibrosis.
Diabetes Drugs Compared for NAFLD Treatment
Findings of the analysis also revealed that some evidence indicates that liraglutide improves liver fat, liver function, and HbA1c, and may aid in NASH resolution and weight reduction.
Priority Review Granted to Obeticholic Acid for Fibrosis Due to NASH
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for obeticholic acid (Intercept) for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).
Nonalcoholic Fatty Liver Disease May Improve With Diets Low in Glycemic Index, Load
Carbohydrate quality in diet may play a potential role in improvement of hepatic fat mass and ALT level in NAFLD.
Obesity Is the Most Common Risk Factor for Chronic Liver Disease
Whether single or additive, obesity is a significant risk factor for chronic liver disease.
Investigational Ubrogepant Does Not Confer Hepatotoxicity in Healthy Individuals
Investigators aimed to evaluate the safety and tolerability of ubrogepant, focusing on hepatic safety, when administered intermittently with high-frequency dosing in healthy participants.
Tesamorelin May Aid Patients With HIV, Fatty Liver Disease
Tesamorelin significantly reduced hepatic fat fraction compared with placebo
Lanifibranor Gets Fast Track Status for Non-Alcoholic Steatohepatitis
The FDA has granted Fast Track designation to lanifibranor (Inventiva) for the treatment of non-alcoholic steatohepatitis.
Examining Serum Hepatic Enzymes, Lipid Profile, and Glycemic Control in T2D
Researchers found that mean hepatic enzyme levels were jointly and significantly associated with poorly controlled T2D.
Fluoride Exposure Tied to Kidney, Liver Function Changes in Youth
This study’s findings suggest that there may be potential kidney and liver health concerns to consider when evaluating fluoride use and appropriate levels in public health interventions.
Diagnosing Fibrosis Stage in NAFLD: Transient Elastography Better Than Point Shear Wave Elastography
Study results showed that transient elastography was good for the diagnosis of all fibrosis stages and was superior compared with point shear wave elastography for the diagnosis of fibrosis stages ≥F2 and ≥F3.
ARO-AAT Receives Fast Track Status for Treatment of Rare Genetic Liver Disease
The FDA has granted Fast Track designation to ARO-AAT an investigational treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency
Want to read more?
Please login or register first to view this content.